Expanding The Scope of AKT Modulation Through Targeted Protein Degradation

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• AKT is a key regulator of cellular processes and a frequently dysregulated pathway in cancer.
• Traditional AKT inhibitors show limitations in clinical efficacy and toxicity.
• Targeted Protein Degradation (TPD) presents a novel therapeutic approach.

Purpose of the Study:

• To review AKT-targeting PROTACs as a therapeutic strategy in oncology.
• To highlight the advantages of TPD over traditional AKT inhibition.
• To summarize the current landscape of AKT-targeting PROTACs.

Main Methods:

• Literature review of AKT-targeting PROTACs.
• Comparative analysis of PROTACs versus AKT inhibitors.
• Assessment of downstream signaling and antiproliferative effects.

Main Results:

• Numerous AKT-targeting PROTACs have been developed, largely outperforming AKT inhibitors.
• PROTACs exhibit enhanced potency, selectivity, and sustained suppression of AKT activity.
• Improved antiproliferative effects and prolonged inactivation of downstream signaling pathways were observed.

Conclusions:

• AKT remains a critical therapeutic target in oncology.
• PROTACs represent a powerful new pharmacological tool for AKT modulation.
• AKT-targeting PROTACs hold significant potential to expand therapeutic options and elucidate AKT's role in cancer.